| __timestamp | Alnylam Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50561000 | 751040000 |
| Thursday, January 1, 2015 | 41097000 | 889895000 |
| Friday, January 1, 2016 | 47159000 | 1116854000 |
| Sunday, January 1, 2017 | 89912000 | 1313646000 |
| Monday, January 1, 2018 | 74908000 | 1491212000 |
| Tuesday, January 1, 2019 | 219750000 | 1704048000 |
| Wednesday, January 1, 2020 | 492853000 | 1860455000 |
| Friday, January 1, 2021 | 844287000 | 1846275000 |
| Saturday, January 1, 2022 | 1037418000 | 2096039000 |
| Sunday, January 1, 2023 | 1828292000 | 2419226000 |
| Monday, January 1, 2024 | 2248243000 | 2853915000 |
Unlocking the unknown
In the competitive landscape of biotechnology, Alnylam Pharmaceuticals and BioMarin Pharmaceutical have been pivotal players. Over the past decade, BioMarin has consistently outpaced Alnylam in annual revenue, showcasing a robust growth trajectory. In 2014, BioMarin's revenue was approximately 15 times that of Alnylam. Fast forward to 2023, and BioMarin still leads, with revenues reaching nearly $2.4 billion, a 220% increase from 2014. Meanwhile, Alnylam has shown impressive growth, with its revenue surging by over 3,500% to approximately $1.8 billion in the same period. This remarkable growth reflects Alnylam's strategic advancements and market penetration. As both companies continue to innovate, the gap narrows, setting the stage for an intriguing rivalry in the biotech sector. The data underscores the dynamic nature of the industry and the potential for shifts in market leadership.
Pfizer Inc. vs BioMarin Pharmaceutical Inc.: Annual Revenue Growth Compared
Revenue Insights: Amgen Inc. and BioMarin Pharmaceutical Inc. Performance Compared
Comparing Revenue Performance: Sanofi or BioMarin Pharmaceutical Inc.?
Revenue Insights: Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc. Performance Compared
Alnylam Pharmaceuticals, Inc. vs Exelixis, Inc.: Examining Key Revenue Metrics
Alnylam Pharmaceuticals, Inc. vs Halozyme Therapeutics, Inc.: Examining Key Revenue Metrics
Breaking Down Revenue Trends: Alnylam Pharmaceuticals, Inc. vs ImmunityBio, Inc.
Alnylam Pharmaceuticals, Inc. and Mesoblast Limited: A Comprehensive Revenue Analysis
Comparing Revenue Performance: BioMarin Pharmaceutical Inc. or Lantheus Holdings, Inc.?
Annual Revenue Comparison: BioMarin Pharmaceutical Inc. vs HUTCHMED (China) Limited
BioMarin Pharmaceutical Inc. vs ImmunityBio, Inc.: Annual Revenue Growth Compared
Revenue Insights: BioMarin Pharmaceutical Inc. and Celldex Therapeutics, Inc. Performance Compared